Considering that current glaucoma treatments target secondary outflow mechanisms or incur side effects (such as hyperemia) (Sharif, 2023; Weinreb et al., 2002), the IOP lowering achieved through TRPV4 inhibition and gene knockdown promises a novel therapeutic avenue to mitigate ocular injury. This evidence concerns the gene TRPV4 and glaucoma.